[1] Blesl A, Stadlbauer V. The gut-liver axis in cholestatic liver diseases. Nutrients, 2021, 13(3):1-33.
[2] Yan S, Yin X M. Gut microbiome in liver pathophysiology and cholestatic liver disease. Liver Res, 2021, 5(3): 151-163.
[3] Albillos A, De Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol, 2020, 72(3): 558-577.
[4] Tripathi A, Debelius J, Brenner D A, et al. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol, 2018, 15(7): 397-411.
[5] Tilg H, Adolph T E, Trauner M. Gut-liver axis: Pathophysiological concepts and clinical implications. Cell Metab, 2022, 34(11): 1700-1718.
[6] Wahlstrom A. Outside the liver box: The gut microbiota as pivotal modulator of liver diseases. Biochim Biophys Acta Mol Basis Dis, 2019, 1865(5): 912-919.
[7] Chiang J Y L, Ferrell J M. Bile acid metabolism in liver pathobiology. Gene Expr, 2018, 18(2): 71-87.
[8] Wahlstrom A, Sayin S I, Marschall H U, et al. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab, 2016, 24(1): 41-50.
[9] Alabraba E, Nightingale P, Gunson B, et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl, 2009, 15(3): 330-40.
[10] Vera A, Moledina S, Gunson B, et al. Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet, 2002, 360(9349): 1943-1944.
[11] Allegretti J R, Kassam Z, Carrellas M, et al. Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial. Am J Gastroenterol, 2019, 114(7): 1071-1079.
[12] Nakamoto N, Sasaki N, Aoki R, et al. Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis. Nat Microbiol, 2019, 4(3): 492-503.
[13] Sasatomi K, Noguchi K, Sakisaka S, et al. Abnormal accumulation of endotoxin in biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol, 1998, 29(3): 409-416.
[14] Furukawa M, Moriya K, Nakayama J, et al. Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis. Hepatol Res, 2020, 50(7): 840-852.
[15] Chen W, Wei Y, Xiong A, et al. Comprehensive analysis of serum and fecal bile acid profiles and interaction with gut microbiota in primary biliary cholangitis. Clin Rev Allergy Immunol, 2020, 58(1): 25-38.
[16] Tang R, Wei Y, Li Y, et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut, 2018, 67(3): 534-541.
[17] Haruta I, Kikuchi K, Hashimoto E, et al. Long-term bacterial exposure can trigger nonsuppurative destructive cholangitis associated with multifocal epithelial inflammation. Lab Invest, 2010, 90(4): 577-588.
[18] Feld J J, Meddings J, Heathcote E J. Abnormal intestinal permeability in primary biliary cirrhosis. Dig Dis Sci, 2006, 51(9): 1607-1613.
[19] Haruta I, Hashimoto E, Kato Y, et al. Lipoteichoic acid may affect the pathogenesis of bile duct damage in primary biliary cirrhosis . Autoimmunity, 2006, 39(2): 129-135.
[20] Zhao J, Zhao S, Zhou G, et al. Altered biliary epithelial cell and monocyte responses to lipopolysaccharide as a TLR ligand in patients with primary biliary cirrhosis. Scand J Gastroenterol, 2011, 46(4): 485-494.
[21] Vleggaar F P, Monkelbaan J F, Van Erpecum K J. Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study. Eur J Gastroenterol Hepatol, 2008, 20(7): 688-692.
[22] Tabibian J H, Gossard A, El-Youssef M, et al. Prospective clinical trial of rifaximin therapy for patients with primary sclerosing cholangitis. Am J Ther, 2017, 24(1): e56-e63.
[23] Silveira M G, Torok N J, Gossard A A, et al. Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study.Am J Gastroenterol, 2009, 104(1): 83-88. |
